Multiple Sclerosis

A neurodegenerative disease with many faces

Juvisé Pharmaceuticals is committed to helping patients with relapsing-remitting multiple sclerosis.

Over 2.5 million people worldwide suffer from multiple sclerosis(1)

What is Multiple Sclerosis?

Multiple Sclerosis (MS) is a chronic neurological condition, characterized by inflammatory attacks, that impacts the central nervous system (CNS).(1)

 

Multiple sclerosis manifests in three main types:(2)

  • Relapsing-remitting (RR-MS): The most common type, affecting about 90% of MS patients. It is characterized by alternating periods of disease activity and remission, which can leave permanent effects between episodes.
  • Secondary progressive (SP-MS): A late and progressive evolution of the RR-MS form, often occurring years or decades after the initial diagnosis.
  • Primary progressive (PP-MS): A progressive form where symptoms worsen from the start without improvement or periods of remission.

Geographical disparities following a latitudinal gradient, higher prevalence in Europe and North America.(3)

Leading cause of non-traumatic disability in young adults(1)

Multiple sclerosis is two to three times more common in women than in men(1)

Multiple sclerosis typically starts between the ages of 20 and 40(1)

Management of Multiple Sclerosis

A disease modifying treatment (DMT) should be initiated early after diagnosis.(4)

Over the past few decades, a wide range of disease-modifying therapies (DMTs) have been developed, targeting different mechanisms involved in the progression of multiple sclerosis (MS).(4)

The current treatment approach focuses on reducing the risk of relapses and slowing the progression of disability. The expanding range of therapies also offers new possibilities for personalized treatment.(5)

At Juvisé Pharmaceuticals, we are dedicated to collaborating with the scientific community and patients to enhance MS management together.

References

1. Montalban X et al. Eur J Neuro. 2018.(25):215-237.
2. European Multiple Sclerosis Platform. MS Barometer 2020. Brussels.
3. Mallawaarachchi et al. Multiple Sclerosis and related disorders. 2024.(81):105153.
4. Redfern JS. Immunopathophysiologic basis of MS and implications for therapy-a narrative review. Pharm Pharmacol Int J. 2021;9(6):263‒271. DOI: 10.15406/ppij.2021.09.00355.

JUV-FRA-202408-0211, 09/2024